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57 Abstract
58 Background and Objectives: To date, the effects of FFP and PC storage duration on mortality have 
59 only been studied in a few studies in limited patient subpopulations. The aim of the current study was 
60 to determine if FFP and PC storage duration is associated with increased in hospital mortality risk 
61 across cardiac surgery, acute medicine, ICU and orthopaedic surgery patients.
62
63 Materials and Methods: Two-stage individual patient data meta-analyses were performed to 
64 determine the effects of FFP and PC storage duration on in hospital mortality. Preset random effects 
65 models were used to determine pooled unadjusted and adjusted (adjusted for age, gender and units 
66 of product transfused) effect estimates. 
67
68 Results: The FFP storage duration analysis included 3625 patients across 4 studies. No significant 
69 association was observed between duration of storage and in hospital mortality in unadjusted 
70 analysis, but after adjusting for patient age, gender and units of product a small increased risk of in 
71 hospital mortality was observed for each additional month of storage (OR 1.05, 95% CI 1.01-1.08). 
72 This effect was no longer statistically significant when donor ABO blood group was 
73 incorporated into the random effects model on post hoc analyses. A total of 547 patients across 
74 5 studies were incorporated in the PC storage duration analysis. No association was observed 
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77 Conclusions: There is insufficient evidence to support shortening FFP or PC shelf life based on in 
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79 Introduction
80 Fresh frozen plasma (FFP) and platelet concentrates (PCs) are transfused either prophylactically 
81 or therapeutically to replace clotting factors or improve primary hemostasis, respectively. FFPs 
82 and PCs are prepared from whole blood or collected directly via apheresis. FFPs contain plasma 
83 proteins, while PCs contain concentrated platelets in a mixture of additive solution and plasma. 
84 Depending on the jurisdiction, FFPs have shelf lives of 3-24 months at -18°C to -30°C and PCs can 
85 be stored for 4-7 days at 20-24°C [1-3].
86
87 Recently, there has been increasing concern that blood product storage duration is associated with 
88 decreased transfusion efficacy and safety. The relationship between FFP storage duration and 
89 mortality has only been investigated in one observational study of 10,626 coronary artery bypass graft 
90 patients [4]. Transfusion of FFP stored for greater than 323 days was associated with increased risks 
91 of 30-day mortality. Similarly in a meta-analysis of 46 clinical studies, fresh PCs demonstrated 
92 superior 1 hour corrected count increment (CCI), 24 hour CCI, platelet recovery and platelet survival 
93 compared to stored PCs [5]. It follows that stored PCs may be associated with shorter transfusion 
94 intervals in haematological patients however, this effect has not been seen in all studies [6, 7]. 
95 The relationship between PC storage duration and mortality has been examined less extensively in 
96 other clinical settings with studies in trauma, cardiac surgery and bone marrow transplant patients 
97 only [8-10]. Inaba et al. linked stored PC transfusion with increased rates of sepsis but not mortality in 
98 381 trauma patients after controlling for Injury Severity Score, head Abbreviated Injury Score and 
99 platelet mismatch between groups [8]. Further research is required to determine if this correlation can 
100 be replicated and applied to other patient subgroups before considering alterations to shelf life.
101
102 This study aimed to determine if FFP and PC storage duration is associated with increased in 
103 hospital mortality risk in cardiac surgery, acute medicine, ICU and orthopaedic surgery patients. This 
104 will be achieved by completing subset analysis of individual patient data previously collected for 
105 packed red blood cell (PRBC) storage duration analysis [11].
106
107 Methods
108 Study selection, data extraction and synthesis
109 Institutional ethics approvals were acquired from the University of Queensland (2016-SOMILRE-0175) 
110 and The Alfred Hospital (378/14) prior to initiation of study.  Study selection, data extraction and 
111 synthesis have been described previously for a PRBC storage duration analysis [11]. In brief, 
112 observational studies published between 1994-2017 reporting associations between duration 
113 of storage of PRBCs and clinical outcomes were identified from EMBASE and PubMed 
114 (keyword and search strategy is detailed in [12]) and assessed by two investigators. The 
115 corresponding authors of each paper were contacted to request access to individual patient data 
116 (IPD).  Studies that also reported mean FFP or mean PC storage duration were included in the 
117 current study (Figure 1).  Patients who received FFP or PC transfusions (in addition to PRBC 
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120 Data analysis
121 The outcome of interest was in hospital mortality. Where multiple units were transfused and individual 
122 unit storage durations were available, the mean age of the aggregate units was determined. PC 
123 duration of storage was analysed using the original scale (i.e. days) and FFP was rescaled (by 
124 dividing by 30.25) and analysed using month as the unit of time. Two-stage meta-analyses were 
125 performed to determine the effects of duration of blood product storage on in hospital mortality. For 
126 each product, logistic regression models were fitted to derive odds ratios (ORs) and 95% confidence 
127 intervals (CI) for each study.  Age, gender and units of product transfused were included as 
128 covariates in the adjusted models.  Paper-level coefficients (log(OR)) were then combined using a 
129 random effects model. Post hoc analyses were completed for the FFP analyses to test for the 
130 confounding effects of ABO blood group.  I2 statistics were used to assess for heterogeneity. All 
131 analyses were performed using STATATM (StataCorp 2017, version 15.0). 
132
133 Results
134 Of 18,322 patient observations from 16 studies in the source dataset [11] 1,133 babies were 
135 excluded. Of 17,199 patients remaining, 3,929 (23%) had received FFP. Of these, 3,625 patients from 
136 4 studies were included in analysis after excluding 299 without storage duration data and 5 with 
137 missing mortality data (figure 1) [13-16]. Of 17,199 eligible patients, 856 (5%) received platelet 
138 concentrate of whom 133, known to have received frozen product, were excluded. Of the 723 
139 remaining, 547 (76%) patients who received fresh platelets had sufficient data on storage duration for 
140 inclusion in analyses (figure 1). Summary statistics for those included are shown in Table 1. The two 
141 studies with the oldest FFP storage durations were conducted in the Netherlands, however, patients 
142 were recruited 10 years apart [11]. 547 patient entries were incorporated in the PC storage duration 
143 analyses across 5 papers [13, 14, 17-19] (Figure 1).  Mean PC storage duration was consistent 
144 across included studies ranging between 3 to 4 days.  The mean age of patients in the FFP analysis 
145 was 61 years with 39% between 40-65 years old and 50% greater than 65 years old.  The median 
146 units of FFP transfused in the FFP analysis was 6 units (IQR: 3-12) and the mean storage duration of 
147 FFP transfused was 8.9 ± 5.1 standard deviation (SD) months.  
148
149 FFP storage duration expressed as months was not associated with  in hospital mortality in 
150 unadjusted analyses (OR, 1.01 95% CI 0.96-1.05 per month, Table 2).   After adjusting for the units of 
151 FFP transfused and patient’s age and gender a 5% increase in the odds of in hospital mortality per 
152 additional month of FFP storage was observed (OR 1.05, 95% CI 1.01-1.08, Figure 2). The I2 statistic 
153 was 0.0% demonstrating minimal heterogeneity between studies. When analyses were also adjusted 
154 for donor ABO blood group post hoc, effect estimates were consistent but more imprecise, failing to 
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157 Results for PC meta-analyses are shown in Table 3 and Figure 3. There was no evidence for an 
158 association between duration of storage and in hospital mortality in either unadjusted or adjusted 
159 analyses. The  I2 statistic was 0.0% demonstrating minimal heterogeneity.  
160
161 Discussion
162 Each additional month of FFP storage was associated with a small increased risk of in hospital 
163 mortality when adjusted for age, gender and number of units transfused. This effect was not 
164 statistically significant when donor ABO blood group was included on post hoc analyses. These 
165 results differ from the findings of Van Straten et al. whereby FFPs stored for greater than 323 days 
166 were linked to 3.43 increased odds of 30-day mortality in 10,626 cardiac surgery patients [4].  
167 Notably, the mean age of patients in the study by Van Straten et al. was 65-66 years old with the 
168 majority of patients being male [4]. It is possible that older cardiac surgery patients may be more 
169 susceptible to FFP storage events compared to other patient subgroups.  Furthermore, the study by 
170 Van Straten et al. may have included more patients who received non-leukoreduced FFPs compared 
171 to our pooled patient analysis as only FFPs produced after 2001 were leukoreduced (recruitment 
172 period 1998-2007) [4].  Leukoreduced blood products have been associated with decreased cytokine 
173 and microparticle accumulation along with reduced endothelial dysfunction post-transfusion.  Higher 
174 proportions of leukoreduced products in our pooled patient analysis may have abrogated the adverse 
175 effects seen in previous studies. Differences in other confounders such as year of transfusion may 
176 also explain differences in the findings. Van der Bom et al. observed that the duration of FFP storage 
177 prior to transfusion varied significantly between calendar years [20]. Unfortunately, the year of each 
178 transfusion was not available in this dataset so it was not possible to assess this effect. 
179
180 Notably, this pooled patient meta-analysis also delivered results relevant to countries with short FFP 
181 storage durations (e.g. 12 months) such as Australia and Canada [21-24].  For example, FFP is stored 
182 for 12 months with most FFP transfused within the first 3 months of storage in Australia.  It follows 
183 that expressing FFP storage duration in months is more applicable for these jurisdictions compared to 
184 an arbitrary cut-off at 323 days [4].
185
186 PC storage duration was not associated with in hospital mortality risk in a predominantly acute 
187 medical patient population.  This is similar to previous studies in cardiac surgery, bone marrow 
188 transplant and trauma patients [8-10].  Together, these results demonstrate the absence of any 
189 relation between PC storage duration up to 5 days and mortality.  This is reassuring as PCs can be 
190 up to 3 days old by the time they have passed viral screening and are released to administering 
191 institutions; meaning that the effective shelf life of PCs is only 2-5 days [25].  Any shortening of PC 
192 shelf life would likely lead to significant PC wastage [26].  Notably, it is possible that the relationship 
193 between PC storage duration and mortality only manifests at the extremes of storage (> 5 days) 
194 similar to PRBCs.  It follows that the results from this pooled patient analysis may not apply to 
195 jurisdictions where PCs are stored for up to 7 days such as United States of America, United 
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197
198 These clinical results differs from laboratory data showing that PCs undergo functional and structural 
199 changes leading to disturbances in platelet activation, aggregation and immune function [28-31]. 
200 Notably, there is a very wide range of platelet counts, cytokines and biological response mediators 
201 among PCs [32]. The adverse effects of PC storage duration on mortality may be obscured by the 
202 variability between different PCs. Furthermore, the relative rarity of mortality in patients receiving PCs 
203 may mask any storage duration-related adverse events. 
204
205 This pooled patient analyses had several limitations. Firstly, this study only investigated mortality to 
206 enhance study inclusion.  It is possible that morbidity indices such as nosocomial infection and 
207 prolonged hospital length of stay are more sensitive to storage lesions compared to mortality. 
208 Furthermore, this study was vulnerable to unmeasured confounding factors as it pooled data 
209 from observational trials across the world.  The FFP storage duration analysis would be most 
210 susceptible to these effects as FFP preparation, storage and thawing protocols differ widely within 
211 and across jurisdictions.  Time to FFP freezing, speed of freezing and duration of storage post-thaw 
212 affect coagulation factor and microparticle concentration [33-35].  This study only examined the 
213 relationship between frozen FFP storage duration and mortality as other FFP information was not 
214 available.  As such, differences in FFP preparation and post-thaw storage duration would manifest as 
215 increased variability (leading to reduced power) or confounding factor (potentially skewing results).  
216 Further clinical studies are required to determine if post-thaw FFP storage duration is associated with 
217 an increased risk of mortality. Changes in transfusion guidelines over time may have led to additional 
218 confounding due to the long recruitment period (1993-2010) across the included studies.  This effect 
219 was likely insignificant as the effect estimates were similar across studies in the FFP analyses (except 
220 the study by Kadar et al. [13]) regardless of recruitment time (Table 2). Lastly, all patients in this 
221 study received PRBCs as this is a secondary analysis from the PRBC storage duration IPD 
222 analysis. Further studies are required to determine if the findings from this study applies to 
223 patients who only received PCs or FFPs. 
224
225 In this pooled patient analysis, PC storage duration was not associated with in hospital mortality. Each 
226 additional month of FFP storage duration was not associated with increased in hospital mortality risk, 
227 after controlling for donor ABO blood group. There is insufficient evidence to curtail PC or FFP shelf 
228 life based on mortality risk. 
229
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Age (years) (mean (SD)) 46.0 (25.8) 60.9 (17.7)
<40 years old (count, %) 196 (35.8) 371 (10.2)
40-65 years old (count, %) 186 (34.0) 1,424 (39.3)
>65 years old (count, %) 165 (30.2) 1,830 (50.5)
Gender (male; count, %) 334 (61) 2,489 (69)
Median units of PRBC transfused 
[Median (IQR)]
6 (3-12) 5 (3-7)
Median units of product* transfused 
[Median (IQR)] 2 (1-4) 2 (2-4)
Mean age of product* transfused (mean 
(SD))
3.2 (1.3) days 8.9 (5.1) months
In hospital mortality (count, %) 187 (34.2) 645 (17.8)
Clinical setting
Cardiac surgery (count, %) 0 (0.0) 1429 (39.4)
Acute medicine (count, %) 386 (70.6) 1931 (53.3)
Intensive care unit (count, %) 150 (27.4) 251 (6.9)
Orthopaedic surgery (count, %) 11 (2.0) 14 (0.4)
Geographic location
Americas (count, %) 72 (13.2) 1429 (39.4)
Europe (count, %) 464 (84.8) 1931 (53.3)
Middle East (count, %) 11 (2.0) 14 (0.4)
ANZ (count, %) 0 (0.0) 251 (6.9)
ANZ=Australia and New Zealand. FFP=fresh frozen plasma. PRBC=packed red blood cells. 
*Product is PC or FFP respectively
Table 2. : Estimated effect (odds ratio) of fresh frozen plasma storage duration (per month) on risk 
of mortality. Unadjusted and adjusted mortality ORs as a function of mean FFP storage duration 
expressed in months














Kadar 2013 [36] 1.37 0.68 2.74 0.2 2.32^ 0.58 9.36 0.1
Middelburg 2013 [37] 1.02 0.97 1.07 46.0 1.06 1.00 1.11 47.8
Petilla 2011 [38] 0.94 0.71 1.25 1.4 0.98 0.73 1.31 1.4
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[16]
Pooled Effect 1.01 0.96 1.05 100 0.48 1.05 1.01 1.08 100 0.01
Test for heterogeneity 0.75 0.63
*Adjusted for age, gender, unit of product transfused; ^ adjusted for age only
Table 3. Estimated effect (odds ratio) of platelet concentrate storage duration (per day) on risk of 
mortality Unadjusted and adjusted mortality ORs as a function of mean platelet concentrate storage 
duration (days). 














Gajic 2004 [17] 0.79 0.49 1.27 11.1 0.78 0.48 1.28 11.0
Juffermans 2011 [18] 0.97 0.43 2.19 3.8 0.83^ 0.34 2.05 3.3
Juffermans 2012 [19] 0.83 0.50 1.36 10.0 0.78 0.44 1.37 8.3
Kadar 2013 [36] 2.00 0.51 7.90 1.3 2.06^ 0.50 8.44 1.4
Middelburg 2013 [37] 0.92 0.76 1.10 73.8 0.96 0.80 1.16 76.0
Pooled Effect 0.90 0.77 1.06 100 0.20 0.94 0.79 1.11 100 0.44
Test for heterogeneity 0.78 0.67










This article is protected by copyright. All rights reserved
Figure 1: Selection of studies into FFP and PC analysis. Individual patient datasets from 16 
studies were received from the original PRBC storage duration analysis. Of these datasets, 4 
studies reported FFP storage duration and 5 studies reported mean PC storage duration. Mean 
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Figure 2: Forest plot of mortality risk as a function of mean FFP storage duration in months. 
Logistic regression was used to calculate ORs, adjusted for age, gender and units of FFPs 
transfused. 
Figure 3: Forest plot of mortality risk as a function of mean PC storage duration in days. 
Logistic regression was used to calculate ORs, adjusted for age, gender and units of platelets 
transfused.
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